Rainbow-Asia: A Randomized, Multicenter, Double-Blind, Phase Iii Study Of Ramucirumab Plus Paclitaxel Versus Placebo Plus Paclitaxel In The Treatment Of Advanced Gastric Or Gastroesophageal Junction (Gej) Adenocarcinoma Following Disease Progression On First-Line Chemotherapy With Platinum And Fluoropyrimidine.
JOURNAL OF CLINICAL ONCOLOGY（2021）
摘要
199Background: Ramucirumab (RAM), a fully human IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor 2, has been approved in combination with paclitaxel (PTX) in patients ...
更多查看译文
关键词
Ramucirumab,Paclitaxel,Adenocarcinoma,Placebo,Kinase insert domain receptor,Oncology,Monoclonal antibody,Medicine,Double blind,First line chemotherapy,Internal medicine
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要